Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The SBG 2000-1 trial is a randomised study that investigates if dose-tailored adjuvant FEC therapy based on the individual's leukocyte nadir value can improve outcome. The study has included 1535 women with medium and high-risk breast cancer.
OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind50
Udgave nummer3
Sider (fra-til)329-37
Antal sider9
ISSN0284-186X
DOI
StatusUdgivet - apr. 2011

ID: 33276422